The Unexpected Success of NRTIs in Second-Line Treatment

The Lancet Infectious Diseases - United Kingdom
doi 10.1016/s1473-3099(17)30631-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Second-Line Treatment of Ovarian Cancer

Oncologist
Cancer ResearchMedicineOncology
2000English

Second-Line Treatment Options in Hepatocellular Carcinoma

Drugs in Context
Molecular MedicinePharmacology
2019English

Second-Line Treatment for Renal Cell Cancer

British Journal of Cancer
Cancer ResearchOncology
2012English

Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia

Cancer
Cancer ResearchOncology
2010English

Establishment of a First‑line Second‑line Treatment Model for Human Pulmonary Adenocarcinoma

Oncology Letters
Cancer ResearchOncology
2016English

Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2015English

Ruxolitinib as First-Line Treatment in Secondary Hemophagocytic Lymphohistiocytosis: A Second Experience

American Journal of Hematology
Hematology
2018English

Systemic Treatment in EGFR-ALK NSCLC Patients: Second Line Therapy and Beyond

Expert Review of Anticancer Therapy
OncologyPharmacology
2014English

Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Pathology and Oncology Research
MedicineForensic MedicinePathologyOncologyCancer Research
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy